RS BioTherapeutics develops RSBT-001, a first-in-class therapeutic that utilizes immune-modulating cannabinoids to target pulmonary inflammation in diseases such as COPD and Idiopathic Pulmonary Fibrosis. The company aims to improve treatment efficacy for patients suffering from chronic respiratory conditions by enhancing the bioavailability of therapeutic agents in the lungs.
Funding
$5.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for chronic respiratory diseases characterized by pulmonary inflammation, such as COPD and Idiopathic Pulmonary Fibrosis, often rely on corticosteroids, which can have significant side effects and limited long-term efficacy. There is a need for alternative therapies that can effectively reduce pulmonary inflammation without the drawbacks associated with traditional treatments.
Solution
RS BioTherapeutics is developing RSBT-001, a first-in-class therapeutic agent that utilizes immune-modulating cannabinoids to target pulmonary inflammation at multiple levels within the inflammatory cascade. RSBT-001 is designed as a steroid-free alternative for treating respiratory diseases characterized by pulmonary inflammation, including COPD, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension. The compound harnesses the anti-inflammatory properties of specific cannabinoids and is delivered via a proprietary, polarity adaptive transport mechanism to enhance bioavailability in the lungs. By targeting the inflammatory cascade at multiple points, RSBT-001 aims to provide a more effective and safer treatment option for patients suffering from chronic respiratory conditions. The company is currently targeting an IND filing for RSBT-001.
Target Audience
The primary target audience includes patients suffering from chronic respiratory diseases characterized by pulmonary inflammation, such as COPD, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension, as well as the healthcare providers who treat them.
Features
- First-in-class therapeutic agent utilizing immune-modulating cannabinoids
- Designed as a steroid-free alternative to current treatments
- Targets pulmonary inflammation at multiple levels of the inflammatory cascade
- Proprietary, polarity adaptive transport mechanism for enhanced drug delivery to the lungs
- Demonstrated anti-inflammatory and anti-fibrotic effects in human lung tissue
- Potential application for a range of respiratory diseases including COPD, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension